{"entity": "researcher", "timestamp": "2026-08-22T06:56:36.695Z", "family": "Monteiro", "given": "F\u00e1tima Liliana", "initials": "FL", "orcid": "0000-0002-8438-0332", "affiliations": ["Department of Medical Sciences, Institute of Biomedicine-iBiMED, University of Aveiro, 3810-193 Aveiro, Portugal."], "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/researcher/f6e6e222aed84d8486992b8d40e98aa5.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/researcher/f6e6e222aed84d8486992b8d40e98aa5"}}, "publications": [{"entity": "publication", "iuid": "01390ab2ce884be48530a8af7618b4af", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/01390ab2ce884be48530a8af7618b4af.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/01390ab2ce884be48530a8af7618b4af"}}, "title": "SETD7 Expression Is Associated with Breast Cancer Survival Outcomes for Specific Molecular Subtypes: A Systematic Analysis of Publicly Available Datasets.", "authors": [{"family": "Monteiro", "given": "F\u00e1tima Liliana", "initials": "FL", "orcid": "0000-0002-8438-0332", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/f6e6e222aed84d8486992b8d40e98aa5.json"}}, {"family": "Stepanauskaite", "given": "Lina", "initials": "L", "orcid": "0000-0003-4173-6009", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/742f111301f045c595480a9f3480bc04.json"}}, {"family": "Williams", "given": "Cecilia", "initials": "C", "orcid": "0000-0002-0602-2062", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/872c978997c74e89ae75efd90d592b42.json"}}, {"family": "Helguero", "given": "Luisa A", "initials": "LA", "orcid": "0000-0001-8237-2390", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/797b23be6b5942fdabdf3c7042d208ab.json"}}], "type": "journal article", "published": "2022-12-07", "journal": {"title": "Cancers (Basel)", "issn": "2072-6694", "volume": "14", "issue": "24", "issn-l": "2072-6694"}, "abstract": "SETD7 is a lysine N-methyltransferase that targets many proteins important in breast cancer (BC). However, its role and clinical significance remain unclear. Here, we used online tools and multiple public datasets to explore the predictive potential of SETD7 expression (high or low quartile) considering BC subtype, grade, stage, and therapy. We also investigated overrepresented biological processes associated with its expression using TCGA-BRCA data. SETD7 expression was highest in the Her2 (ERBB2)-enriched molecular subtype and lowest in the basal-like subtype. For the basal-like subtype specifically, higher SETD7 was consistently correlated with worse recurrence-free survival (p < 0.009). High SETD7-expressing tumours further exhibited a higher rate of ERBB2 mutation (20% vs. 5%) along with a poorer response to anti-Her2 therapy. Overall, high SETD7-expressing tumours showed higher stromal and lower immune scores. This was specifically related to higher counts of cancer-associated fibroblasts and endothelial cells, but lower B and T cell signatures, especially in the luminal A subtype. Genes significantly associated with SETD7 expression were accordingly overrepresented in immune response processes, with distinct subtype characteristics. We conclude that the prognostic value of SETD7 depends on the BC subtype and that SETD7 may be further explored as a potential treatment-predictive marker for immune checkpoint inhibitors.", "doi": "10.3390/cancers14246029", "pmid": "36551516", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC9775934"}, {"db": "pii", "key": "cancers14246029"}], "notes": [], "created": "2026-08-20T13:39:58.397Z", "modified": "2026-08-20T13:39:58.547Z"}, {"entity": "publication", "iuid": "808b48c8739043f99e7ed9f1db64df21", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/808b48c8739043f99e7ed9f1db64df21.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/808b48c8739043f99e7ed9f1db64df21"}}, "title": "A Systematic Review to Define the Multi-Faceted Role of Lysine Methyltransferase SETD7 in Cancer.", "authors": [{"family": "Monteiro", "given": "F\u00e1tima Liliana", "initials": "FL", "orcid": "0000-0002-8438-0332", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/f6e6e222aed84d8486992b8d40e98aa5.json"}}, {"family": "Williams", "given": "Cecilia", "initials": "C", "orcid": "0000-0002-0602-2062", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/872c978997c74e89ae75efd90d592b42.json"}}, {"family": "Helguero", "given": "Luisa A", "initials": "LA", "orcid": "0000-0001-8237-2390", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/797b23be6b5942fdabdf3c7042d208ab.json"}}], "type": "journal article", "published": "2022-03-10", "journal": {"title": "Cancers (Basel)", "issn": "2072-6694", "volume": "14", "issue": "6", "issn-l": "2072-6694"}, "abstract": "Histone-lysine N-methyltransferase SETD7 regulates a variety of cancer-related processes, in a tissue-type and signalling context-dependent manner. To date, there is no consensus regarding SETD7\u00b4s biological functions, or potential for cancer diagnostics and therapeutics. In this work, we summarised the literature on SETD7 expression and function in cancer, to identify the contexts where SETD7 expression and targeting can lead to improvements in cancer diagnosis and therapy. The most studied cancers were found to be lung and osteosarcoma followed by colorectal and breast cancers. SETD7 mRNA and/or protein expression in human cancer tissue was evaluated using public databases and/or in-house cohorts, but its prognostic significance remains inconclusive. The most studied cancer-related processes regulated by SETD7 were cell proliferation, apoptosis, epithelial-mesenchymal transition, migration and invasion with special relevance to the pRb/E2F-1 pathway. SETD7 consistently prevented epithelial to mesenchymal transition in different cancer types, and inhibition of its function appears to be associated with improved response to DNA-damaging agents in most of the analysed studies. Stabilising mutations in SETD7 target proteins prevent their methylation or promote other competing post-translational modifications that can override the SETD7 effect. This indicates that a clear discrimination of these mutations and competing signalling pathways must be considered in future functional studies.", "doi": "10.3390/cancers14061414", "pmid": "35326563", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC8946661"}, {"db": "pii", "key": "cancers14061414"}], "notes": [], "created": "2026-08-20T13:39:43.786Z", "modified": "2026-08-20T13:39:43.916Z"}]}